Eckard Weber, M.D.
CEO and President, Sonexa Therapeutics
Partner, Domain Associates
Eckard Weber, M.D. is the CEO and President of Sonexa and is also a partner at Domain Associates. Dr. Weber joined Domain in 2001 where he has specialized in creating companies around promising new pharmaceutical products. He has been founding CEO of multiple biopharmaceutical companies in the Domain portfolio including Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia, Domain Antibacterial Acquisition Corporation, NovaCardia, Novacea, Novalar Pharmaceuticals, Ocera Therapeutics, Orexigen Therapeutics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics and Tragara Pharmaceuticals. He currently serves as interim CEO of Sonexa Therapeutics, a seed-stage biopharmaceutical company. He is Chairman of the Board at Ascenta Therapeutics, Ocera Therapeutics, Orexigen Therapeutics, Sequel Pharmaceuticals, and Tobira Therapeutics. He was Chairman of Peninsula Pharmaceuticals until the company was sold to Johnson & Johnson in 2005, Chairman of Cerexa until the company was sold to Forest Laboratories in January 2007, Chairman of NovaCardia until the company was sold to Merck in September of 2007, Chairman of Calixa Therapeutics until the company was sold to Cubist Pharmaceuticals in December 2009 and a Board member of Conforma Therapeutics and Cabrellis Pharmaceuticals until they were sold to Biogen-IDEC and Pharmion, respectively. Until 1995, Dr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. He has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. He is the inventor or co-inventor of over 40 patents and patent applications, and he has published over 130 papers in scientific periodicals. Dr. Weber received medical degree from the University of Ulm Medical School, Germany and spent 2 years in postdoctoral training at Stanford University Medical School.
Martin Koller, M.D., M.P.H.
Chief Medical Officer
Martin Koller, M.D., M.P.H is the Chief Medical Officer and joined Sonexa in 2009. He has 20 years of Pharmaceutical Industry experience in neurologic and psychiatric drug development from Phases 1-4. Immediately prior to joining Sonexa, Dr. Koller was an independent consultant to a number of small and medium sized pharmaceutical and biotechnology companies. For 14 years, he worked at Athena Neurosciences and Elan Pharmaceutical where he rose through the ranks to become Vice President of Clinical Development overseeing an international drug development group. He also held past positions at Syntex and Wyeth. Dr. Koller has been involved with a number of INDs and NDAs over the past 20 years in several indications (e.g., Alzheimer's disease, Multiple Sclerosis, cervical dystonia, pain, anti-epileptics, migraine, stroke, anxiety, depression, etc). He received his M.D. degree from the University of Maryland at Baltimore and his M.P.H. degree with an emphasis in epidemiology from the University of Texas at Houston.
Chief Financial Officer
Lynne R. Rollins has over 25 years experience in the healthcare industry in the areas of finance and business development. Currently Ms. Rollins is the CFO for numerous start-up pharmaceutical and medical device companies. Prior to that, she was with Baxter Healthcare Corporation for 19 years. Her positions there included Vice President of Business Development for the Cardiopulmonary Business of the Cardiovascular Group, Vice President of Finance for the Cardiopulmonary Business (Bentley Division) and numerous finance positions within the Hospital Products Group of the Corporation. Ms. Rollins received her Bachelor of Science degree in Finance from California State University and her MBA from Pepperdine University.
Tilman Oltersdorf, M.D.
Executive Vice President, Research and Development
Tilman Oltersdorf, M.D. is the Executive Vice President, Research and Development. He has over 20 years of experience in the biotechnology industry, primarily in start-up companies. His background is both in preclinical and clinical development ranging from molecular neurosciences and molecular oncology to executing phase II clinical studies. He published over 50 scientific papers including articles in Nature, Science and Cell. Prior to Sonexa he was at Idun Pharmaceuticals, Neurocrine Biosciences and Athena Neurosciences (now Elan). He received his medical degree from the University of Freiburg, Germany, worked as a resident in clinical Neurology and spent 4 years as a research fellow at the German Cancer Research Center in Heidelberg with Harald zur Hausen (Nobel laureate).
Barbara M. Finn
Senior Vice President, Regulatory Affairs and Quality Assurance
Barbara Finn is the Senior Vice President of Regulatory Affairs and Quality Assurance. She has 30 years of experience in the pharmaceutical industry with over 20 years in Regulatory Affairs interacting with North American and European Health Authorities in support of both clinical and marketing applications. Prior to Sonexa, Barbara was at Neurocrine Biosciences for 8 years and Quintiles for almost 8 years, where she was the lead for the US NDA and EU MAA for Aricept® (donepezil). Prior to Quintiles, Barbara was at Novartis (Ciba-Geigy) for 13 years. She is a frequent presenter at RAPs and local regulatory forums and a former faculty member for the San Diego State University Regulatory Masters program. Barbara holds a B.S. in Chemistry.